Clinical Trial Update: Single Ascending Oral Dose Study of F901318 [Phase 1]

View source ↗

Summary

A Phase 1 single ascending oral dose study of F901318 in invasive aspergillosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Drugs mentioned

• F901318

Snippet

Sponsor: F2G Biotech GmbH | Conditions: Invasive Aspergillosis | Phase 1 | Status: COMPLETED